These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34565669)

  • 1. The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model.
    Eggermont AMM; Bellomo D; Dwarkasing J; Meerstein-Kessel L; Meves A
    Eur J Cancer; 2021 Nov; 157():518-519. PubMed ID: 34565669
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
    Kawada T
    Eur J Cancer; 2021 Nov; 157():516-517. PubMed ID: 34420836
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
    Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.
    Arias-Mejias SM; Quattrocchi E; Tempel D; Luna-Vargas M; Chen J; Murphree DH; Gjorgova Gjeorgjievski S; Lehman JS; Bridges AG; Dwarkasing J; Meves A
    Int J Dermatol; 2020 Nov; 59(11):e431-e433. PubMed ID: 32516450
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
    Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
    Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of expression of DNA repair genes and relapse from melanoma.
    Jewell R; Conway C; Mitra A; Randerson-Moor J; Lobo S; Nsengimana J; Harland M; Marples M; Edward S; Cook M; Powell B; Boon A; de Kort F; Parker KA; Cree IA; Barrett JH; Knowles MA; Bishop DT; Newton-Bishop J
    Clin Cancer Res; 2010 Nov; 16(21):5211-21. PubMed ID: 20705614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
    Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
    Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining texture features of whole slide images improves prognostic prediction of recurrence-free survival for cutaneous melanoma patients.
    Peng Y; Chu Y; Chen Z; Zhou W; Wan S; Xiao Y; Zhang Y; Li J
    World J Surg Oncol; 2020 Jun; 18(1):130. PubMed ID: 32546168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.
    Tas F; Erturk K
    Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma MicroRNA signature predicts post-recurrence survival.
    Segura MF; Belitskaya-Lévy I; Rose AE; Zakrzewski J; Gaziel A; Hanniford D; Darvishian F; Berman RS; Shapiro RL; Pavlick AC; Osman I; Hernando E
    Clin Cancer Res; 2010 Mar; 16(5):1577-86. PubMed ID: 20179230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival.
    Conway C; Mitra A; Jewell R; Randerson-Moor J; Lobo S; Nsengimana J; Edward S; Sanders DS; Cook M; Powell B; Boon A; Elliott F; de Kort F; Knowles MA; Bishop DT; Newton-Bishop J
    Clin Cancer Res; 2009 Nov; 15(22):6939-46. PubMed ID: 19887478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNAs as biomarkers for recurrence in melanoma.
    Friedman EB; Shang S; de Miera EV; Fog JU; Teilum MW; Ma MW; Berman RS; Shapiro RL; Pavlick AC; Hernando E; Baker A; Shao Y; Osman I
    J Transl Med; 2012 Aug; 10():155. PubMed ID: 22857597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
    Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
    Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
    Lee AY; Droppelmann N; Panageas KS; Zhou Q; Ariyan CE; Brady MS; Chapman PB; Coit DG
    Ann Surg Oncol; 2017 Apr; 24(4):939-946. PubMed ID: 27804026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
    Podlipnik S; Carrera C; Boada A; Richarz NA; López-Estebaranz JL; Pinedo-Moraleda F; Elosua-González M; Martín-González MM; Carrillo-Gijón R; Redondo P; Moreno E; Malvehy J; Puig S
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):857-862. PubMed ID: 30702163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.